Atara biotherapeutics presents updated tab-cel® clinical effectiveness data at asco 2023

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced updated effectiveness and safety data for tabelecleucel (tab-cel® or ebvallo™) from the multicenter expanded access program (eap) study in europe. the results will be featured in a poster presentation at th.
ATRA Ratings Summary
ATRA Quant Ranking